Targeting metabolic adaptive responses to chemotherapy
Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPARα, PPARδ, or PGC1α. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPARα, PPARδ, or PGC1α can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.
1. A method of treating a subject suffering from chronic myelogenous leukemia (CML), the method consisting of administering to the subject a combination therapy consisting essentially of:
a therapeutically effective amount of at least one compound that inhibits mTOR selected from the group consisting of rapamycin, everolimus, temsirolimus, Torin1, and BEZ235; and
a therapeutically effective amount of at least one inhibitor of PPARα, PPARδ, or PGC1α, wherein said inhibitor of PPARα, PPARδ, or PGC1α is an antagonist or an inverse agonist of PPARα, PPARδ, or PGC1α, and wherein said inhibitor is selected from the group consisting of GW6471, GSK3787, GSK0660, and ST237.
2. The method of claim 1 , wherein the at least one compound that inhibits mTOR comprises at least one compound that inhibits BCR-ABL.
3. The method of claim 1 , wherein the at least one compound that inhibits mTOR is rapamycin.
4. The method of claim 1 , wherein the at least one compound that inhibits mTOR and the at least one inhibitor of PPARα, PPARδ, or PGC1α are administered concurrently.
5. The method of claim 1 , wherein the at least one compound that inhibits mTOR and the at least one inhibitor of PPARα, PPARδ, or PGC1α are administered separately.
6. The method of claim 1 , wherein the at least one inhibitor of PPARα, PPARδ, or PGC1α comprises at least one inverse agonist of PPARδ.
7. The method of claim 6 , wherein the at least one compound that inhibits mTOR and the at least one inverse agonist of PPARδ are administered concurrently.
8. The method of claim 6 , wherein the at least one compound that inhibits mTOR and the at least one inverse agonist of PPARδ are administered separately.
9. A method of treating a subject suffering from chronic myelogenous leukemia, the method consisting of administering to the subject a combination therapy consisting essentially of:
a therapeutically effective amount of an inhibitor of mTOR selected from the group consisting of rapamycin, everolimus, temsirolimus, Torin 1, and BEZ235, and a therapeutically effective amount of ST247.
10. The method of claim 9 , wherein the inhibitor of mTOR is rapamycin.